SG11201805387RA - Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists - Google Patents
Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonistsInfo
- Publication number
- SG11201805387RA SG11201805387RA SG11201805387RA SG11201805387RA SG11201805387RA SG 11201805387R A SG11201805387R A SG 11201805387RA SG 11201805387R A SG11201805387R A SG 11201805387RA SG 11201805387R A SG11201805387R A SG 11201805387RA SG 11201805387R A SG11201805387R A SG 11201805387RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical agents
- meta
- benzoic acid
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562273246P | 2015-12-30 | 2015-12-30 | |
PCT/US2016/069511 WO2017117538A1 (en) | 2015-12-30 | 2016-12-30 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805387RA true SG11201805387RA (en) | 2018-07-30 |
Family
ID=57868367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805387RA SG11201805387RA (en) | 2015-12-30 | 2016-12-30 | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
Country Status (16)
Country | Link |
---|---|
US (3) | US10035778B2 (he) |
EP (2) | EP3738953A1 (he) |
JP (1) | JP2019500355A (he) |
KR (1) | KR20180107121A (he) |
CN (1) | CN108779077A (he) |
AU (1) | AU2016381336A1 (he) |
BR (1) | BR112018012981A2 (he) |
CA (1) | CA3008023A1 (he) |
CO (1) | CO2018007278A2 (he) |
ES (1) | ES2806276T3 (he) |
HK (1) | HK1244806A1 (he) |
IL (1) | IL259951A (he) |
PH (1) | PH12018501362A1 (he) |
RU (1) | RU2729518C2 (he) |
SG (1) | SG11201805387RA (he) |
WO (1) | WO2017117538A1 (he) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018012981A2 (pt) * | 2015-12-30 | 2018-12-04 | Saint Louis University | derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas |
CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
JP7540998B2 (ja) | 2018-08-29 | 2024-08-27 | モーフィック セラピューティック,インコーポレイテッド | αvβ6インテグリンの阻害 |
US20230008367A1 (en) | 2019-09-26 | 2023-01-12 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
TW202135811A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
JPWO2021230325A1 (he) * | 2020-05-14 | 2021-11-18 | ||
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
JPWO2023085396A1 (he) * | 2021-11-12 | 2023-05-19 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639765A (en) | 1995-01-17 | 1997-06-17 | G. D. Searle & Co. | Guanidinoalkyl glycine β-amino acids useful for inhibiting bone loss |
US5602155A (en) | 1995-01-17 | 1997-02-11 | G. D. Searle & Co. | Platelet aggregation inhibitors |
US5681820A (en) | 1995-05-16 | 1997-10-28 | G. D. Searle & Co. | Guanidinoalkyl glycine β-amino acids useful for inhibiting tumor metastasis |
US6013651A (en) * | 1995-08-30 | 2000-01-11 | G. D. Searle & Co. | Meta-azacyclic amino benzoic acid compounds and derivatives thereof |
DE69613985T2 (de) | 1995-08-30 | 2002-06-13 | G.D. Searle & Co., Chicago | Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten |
US6100423A (en) | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
DE69706407T2 (de) | 1996-03-29 | 2002-05-29 | G.D. Searle & Co., Chicago | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN |
WO1997036859A1 (en) | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
CA2250690A1 (en) | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Cinnamic acid derivatives and their use as integrin antagonists |
JP2000514809A (ja) | 1996-07-12 | 2000-11-07 | ジー.ディー.サール アンド カンパニー | キラルβ―アミノ酸の不斉合成 |
US6172256B1 (en) | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
ZA991107B (en) | 1998-03-04 | 2000-02-14 | Searle & Co | Process for preparing 3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino] benzoic acid. |
ZA991105B (en) | 1998-03-04 | 2000-02-11 | Searle & Co | Synthesis of chiral beta-amino acids. |
ZA994406B (en) | 1998-03-04 | 2000-02-11 | Searle & Co | Meta-azacyclic amino benzoic acid and derivatives thereof. |
AR015759A1 (es) | 1998-04-10 | 2001-05-16 | Searle & Co | Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones |
CN1346282A (zh) | 1998-12-23 | 2002-04-24 | G.D.西尔公司 | 在肿瘤的治疗中使用环加氧酶-2-抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法 |
US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
KR20030043955A (ko) | 2000-09-08 | 2003-06-02 | 파마시아 이탈리아 에스.피.에이. | 화학적 예방제로서 엑스메스탄 |
US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
EP1377298B1 (en) | 2001-01-26 | 2006-08-30 | Pfizer Italia S.r.l. | Exemestane for treating hormono-dependent disorders |
PL370080A1 (en) | 2001-10-10 | 2005-05-16 | Pharmacia Italia Spa | Methods for preventing and treating bone loss with steroid compounds |
TWI281470B (en) * | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
AU2003299600A1 (en) * | 2002-12-20 | 2004-07-29 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
CA2540730C (en) | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
CA2741683C (en) | 2008-10-24 | 2016-03-22 | Wake Forest University | Platinum acridine anti-cancer compounds and methods thereof |
DE102009000854A1 (de) | 2009-02-13 | 2010-08-19 | Ernst-Moritz-Arndt-Universität Greifswald | Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens |
EP2406250B1 (en) | 2009-03-11 | 2015-08-12 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
US9090640B2 (en) | 2011-09-02 | 2015-07-28 | Ulrich Bierbach | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
KR20150038185A (ko) * | 2012-07-18 | 2015-04-08 | 세인트 루이스 유니버시티 | 인테그린 길항제로서의 베타 아미노산 유도체 |
US8716226B2 (en) * | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
WO2016172710A2 (en) | 2015-04-24 | 2016-10-27 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
BR112018012981A2 (pt) * | 2015-12-30 | 2018-12-04 | Saint Louis University | derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas |
-
2016
- 2016-12-30 BR BR112018012981-0A patent/BR112018012981A2/pt not_active Application Discontinuation
- 2016-12-30 WO PCT/US2016/069511 patent/WO2017117538A1/en active Application Filing
- 2016-12-30 CA CA3008023A patent/CA3008023A1/en not_active Abandoned
- 2016-12-30 RU RU2018120935A patent/RU2729518C2/ru active
- 2016-12-30 SG SG11201805387RA patent/SG11201805387RA/en unknown
- 2016-12-30 EP EP20169477.5A patent/EP3738953A1/en not_active Withdrawn
- 2016-12-30 AU AU2016381336A patent/AU2016381336A1/en not_active Abandoned
- 2016-12-30 EP EP16829387.6A patent/EP3294716B1/en active Active
- 2016-12-30 CN CN201680081360.6A patent/CN108779077A/zh active Pending
- 2016-12-30 JP JP2018530561A patent/JP2019500355A/ja active Pending
- 2016-12-30 ES ES16829387T patent/ES2806276T3/es active Active
- 2016-12-30 KR KR1020187021837A patent/KR20180107121A/ko unknown
-
2017
- 2017-11-14 US US15/812,986 patent/US10035778B2/en active Active
-
2018
- 2018-03-29 HK HK18104335.6A patent/HK1244806A1/zh unknown
- 2018-06-11 IL IL259951A patent/IL259951A/he unknown
- 2018-06-25 PH PH12018501362A patent/PH12018501362A1/en unknown
- 2018-07-12 CO CONC2018/0007278A patent/CO2018007278A2/es unknown
- 2018-07-30 US US16/049,679 patent/US10577330B2/en active Active
-
2020
- 2020-03-02 US US16/806,963 patent/US20200199079A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10035778B2 (en) | 2018-07-31 |
WO2017117538A1 (en) | 2017-07-06 |
KR20180107121A (ko) | 2018-10-01 |
US20180072684A1 (en) | 2018-03-15 |
CN108779077A (zh) | 2018-11-09 |
RU2729518C2 (ru) | 2020-08-07 |
RU2018120935A3 (he) | 2020-03-20 |
US10577330B2 (en) | 2020-03-03 |
US20190023663A1 (en) | 2019-01-24 |
CA3008023A1 (en) | 2017-07-06 |
ES2806276T3 (es) | 2021-02-17 |
EP3294716B1 (en) | 2020-04-15 |
JP2019500355A (ja) | 2019-01-10 |
US20200199079A1 (en) | 2020-06-25 |
RU2018120935A (ru) | 2020-01-30 |
CO2018007278A2 (es) | 2018-10-10 |
IL259951A (he) | 2018-07-31 |
EP3738953A1 (en) | 2020-11-18 |
HK1244806A1 (zh) | 2018-08-17 |
NZ743308A (en) | 2019-10-25 |
EP3294716A1 (en) | 2018-03-21 |
PH12018501362A1 (en) | 2019-02-27 |
BR112018012981A2 (pt) | 2018-12-04 |
AU2016381336A1 (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201403402VA (en) | Compounds | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201406888QA (en) | Lysin-glutamic acid dipeptide derivatives | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201806424TA (en) | Therapeutic compounds |